Pyxis Oncology, INC Form 4 insider transactions

Jakob Dupont, a Director at Pyxis Oncology, Inc., was granted 45,867 stock options with an exercise price of $1.36.

Pyxis Oncology's Principal Financial & Accounting Officer, Jitendra Wadhane, received grants of 109,461 restricted stock units and 262,635 stock options.

Pyxis Oncology's Director, John L. Flavin, was granted 45,867 stock options with an exercise price of $1.36, vesting fully on the first anniversary of the grant date.

Michael A. Metzger, a Director at Pyxis Oncology, Inc., was granted 45,867 stock options with an exercise price of $1.36.

Pyxis Oncology Director Freda Lewis-Hall was granted 45,867 stock options with a $1.36 exercise price, vesting in one year.

Pyxis Oncology Director Darren S Cline acquired 45,867 stock options with an exercise price of $1.36, vesting in one year.

Pyxis Oncology Director Rachel Humphrey received a grant of 45,867 stock options with an exercise price of $1.36, vesting in one year.

Pyxis Oncology, Inc. Director Santhosh Palani was granted 45,867 stock options with an exercise price of $1.36, vesting in one year.

Pyxis Oncology Director Rachel Humphrey sold shares of common stock in April 2025 under a pre-arranged 10b5-1 trading plan, as disclosed in a Form 4 filing dated March 2026.

Pyxis Oncology's Interim CEO, Thomas Civik, was granted 690,131 stock options with an exercise price of $1.49, vesting over 12 months.

Lara Sullivan, CEO of Pyxis Oncology, acquired stock options for 918,308 shares at an exercise price of $0.98 on March 31, 2025.

Michael A. Metzger, a director of Pyxis Oncology, acquired stock options for 36,979 shares at an exercise price of $0.98 on March 31, 2025.

Jitendra Wadhane, SVP and Chief Accounting Officer of Pyxis Oncology, acquired stock options for 263,782 shares of common stock at an exercise price of $0.98 on March 31, 2025.

Director Rachel Humphrey reports the acquisition of stock options in Pyxis Oncology, Inc.

Director Freda Lewis-Hall acquired stock options in Pyxis Oncology, Inc. on March 31, 2025.

Director Darren Cline acquired stock options in Pyxis Oncology, Inc. on March 31, 2025.

Director Jakob Dupont acquired stock options in Pyxis Oncology, Inc. on March 31, 2025.

Director Santhosh Palani acquired stock options in Pyxis Oncology, Inc. on March 31, 2025.

Thomas Civik, a director at Pyxis Oncology, acquired stock options for 36,979 shares at an exercise price of $0.98 on March 31, 2025.

Pamela Ann Connealy, CFO & COO of Pyxis Oncology, reports acquisition of stock options.

Director John Flavin acquired stock options in Pyxis Oncology, Inc. on March 31, 2025.

Lara Sullivan, CEO of Pyxis Oncology, acquired 1,135,000 stock options on December 23, 2024, vesting fully on December 23, 2025, subject to continued employment.

Pamela Ann Connealy, CFO & COO of Pyxis Oncology, acquired stock options for 310,000 shares on December 23, 2024.

Jitendra Wadhane, SVP and Chief Accounting Officer of Pyxis Oncology, was granted 150,000 stock options on December 23, 2024.

Pyxis Oncology's CFO and COO, Pamela Connealy, has increased her holdings in the company through recent purchases of common stock.

Michael A. Metzger, a director of Pyxis Oncology, acquired stock options for 70,683 shares on June 10, 2024.

Director Santhosh Palani acquired 6,000 shares of Pyxis Oncology common stock on June 7, 2024, through restricted stock units.

Pamela Connealy, CFO & COO of Pyxis Oncology, reports acquiring 328,710 restricted stock units on March 26, 2024, and disposing of 0 shares, resulting in a total beneficial ownership of 1,110,293 shares.

Lara Sullivan, CEO of Pyxis Oncology, acquired stock options for 1,071,242 shares of common stock on March 26, 2024.

Director John Flavin of Pyxis Oncology, Inc. reports acquiring and disposing of common stock on March 26, 2024.